For immediate release
THORASYS WANTS TO HELP THE EARLY DETECTION OF EXACERBATION IN PATIENTS WITH RESPIRATORY DISEASES INCLUDING COVID-19
Montreal, April 3rd 2020 – Thorasys is proud to contribute to the fight against COVID-19 by making its Oscillometry technology available to healthcare providers to enable the early detection of patients with respiratory diseases, including COVID-19, which can worsen into pneumonia.
By detecting small airway dysfunction before it becomes symptomatically apparent, Oscillometry might be able to separate COVID-19 patients whose peripheral lungs are affected – i.e. those at risk of developing pneumonia – from milder cases, thus providing information that may help decide when an augmented intervention is warranted and reduce the hospitalization rate during this crisis. Indeed, according to the WHO, 19% of COVID-19 patients develop severe symptoms that require hospitalization and may lead to life-threatening pneumonia.
With the closure of the pulmonary function laboratories, pulmonary specialists no longer have the necessary tools to assess patients. In fact, according to Dr. Chung-Wai Chow MD, PhD, FRCPC an Associate Professor at the University of Toronto, “this is an opportunity to promote oscillometry as a tool for monitoring lung function as it does not have the risk of aerosol generation. With predictions for the pandemic to last three to six months, it is worrisome to navigate as we are now virtually blind in caring for patients with lung disease – whether it is lung transplantation or chronic respiratory diseases. “
Oscillometry is a fast, easy lung function test performed during regular, quiet tidal breathing without coordinated patient efforts or forced expiration. Tests do not require highly trained staff and can readily be carried out in an ambulatory setting or even in the patient’s home.
Thorasys is a small medium-sized enterprise (SME), based in Montreal, Quebec, Canada, which designs, manufactures and markets respiratory medical devices such as the tremoflo. Thorasys applies state-of-the-art research and technology in the development of products for the assessment and monitoring of lung diseases such as asthma, COPD and cystic fibrosis.
M : 514.778.9747